Active Ingredient History
Fingolimod (FTY720) is a sphingosine 1-phosphate receptor modulator indicated and approved for the treatment of relapsing-remitting multiple sclerosis. Fingolimod (trade name Gilenya, Novartis) is metabolized by sphingosine kinase to the active metabolite, fingolimod-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphate receptor modulator, and binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which fingolimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system. Fingolimod was approved as a first-in-class, orally active drug for relapsing multiple sclerosis in 2010, and its applications in other disease conditions are currently under clinical trials. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Accidents (Phase 2)
Amyotrophic Lateral Sclerosis (Phase 2)
Asthma (Phase 2)
Astrocytoma (Early Phase 1)
Autonomic Nervous System Diseases (Phase 4)
Brain Diseases (Phase 4)
Brain Edema (Early Phase 1)
Breast Neoplasms (Phase 1)
Cerebral Hemorrhage (Early Phase 1)
Cognition (Phase 4)
COVID-19 (Phase 2)
Depression (Phase 4)
Dermatitis, Atopic (Phase 1/Phase 2)
Glioblastoma (Early Phase 1)
Healthy Volunteers (Phase 1)
Hemorrhage (Phase 1)
Hypesthesia (Early Phase 1)
Inflammation (Phase 2)
Intracranial Hemorrhage, Hypertensive (Early Phase 1)
Kidney Transplantation (Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 4)
Multiple Sclerosis, Chronic Progressive (Phase 3)
Multiple Sclerosis, Relapsing-Remitting (Phase 4)
Neuritis (Phase 2)
Pain (Early Phase 1)
Paresthesia (Phase 1)
Renal Insufficiency (Phase 1)
Rett Syndrome (Phase 1/Phase 2)
Safety (Phase 1)
Schizophrenia (Phase 2)
Stroke (Phase 2)
Substance-Related Disorders (Phase 1)
Therapeutic Equivalency (Phase 1)
Uveitis (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
